Sigma Healthcare (ASX:SIG) has undergone a major transformation following the combination with Chemist Warehouse Group, expanding its position across pharmacy retail, wholesale distribution and healthcare services.

The company now operates a larger pharmacy network while focusing on integration, operational efficiency and international expansion opportunities.

Company Overview

Sigma Healthcare operates across pharmacy distribution, retail brands and healthcare products.

Following the combination with Chemist Warehouse Group, the company became the listed owner of one of Australia’s largest pharmacy retail networks. Its operations include Chemist Warehouse, Amcal and Discount Drug Stores brands.

The group also provides wholesale distribution services and develops healthcare-related products for pharmacy customers.

FY26 Performance

Sigma reported its FY26 results for the year ended 30 June 2026, highlighting growth following the combination with Chemist Warehouse.

Revenue increased to A$10.8 billion, while normalised Earnings before interest and tax reached A$1.09 billion. Normalised net profit after tax was reported at A$732.3 million.

The company also continued work on integration activities, with planned synergies expected to be delivered over multiple years.

Business Growth

Sigma continues to focus on expanding its pharmacy network and strengthening its retail presence.

The Chemist Warehouse network remains central to the company’s growth strategy, supported by store expansion and increasing customer reach.

The company is also pursuing international opportunities, with expansion efforts focused on selected overseas markets.

Operational Focus

Integration of the combined Business remains a key priority for Sigma.

The company is focused on improving operational efficiency, capturing expected synergies and supporting pharmacy network growth.

Managing a larger retail and distribution platform will require continued Investment in systems, logistics and customer services.

Factors to Watch

Investors are expected to monitor progress on integration, store expansion and delivery of planned operational improvements.

Key areas include pharmacy network growth, international expansion, cost efficiencies and the company’s ability to maintain earnings momentum.

Regulatory developments affecting pharmacy operations will also remain an important consideration.

Risks

Sigma operates in a regulated healthcare environment where government policy changes may affect pharmacy economics.

Integration of large business operations can involve execution challenges, while international expansion introduces additional regulatory and competitive factors.

Changes in consumer behaviour, operating costs and healthcare market conditions may also influence future performance.

Conclusion

Sigma Healthcare has entered a new phase following the combination with Chemist Warehouse, creating a larger healthcare retail and distribution business.

The company’s future performance will depend on successful integration, operational execution and expansion opportunities. For investors following ASX healthcare stocks, Sigma remains a company to monitor as it develops its broader pharmacy platform.